Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of BMS-986165 vs Placebo and Apremilast in Moderate-to-Severe Plaque Psoriasis
jRCT2080224152Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of deucravacitinib in plaque psoriasis (3 arms), sponsored by Bristol Myers Squibb. Started Nov 2018; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2080224152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224152.